What question did this study set out to answer?

Investigate the effectiveness of durable LVAD therapy as compared to heart transplantation in patients under 50 years of age.

February 9, 2026Open Access

Heart Replacement Therapy in Young Patients

Key Points

Investigate the effectiveness of durable LVAD therapy as compared to heart transplantation in patients under 50 years of age.
Conducted a multicenter study evaluating LVAD therapy using MagLev technology.
Included young adults under 50 years old as potential candidates for heart replacement.
Analyzed survival outcomes associated with LVADs and heart transplantation.
Durable LVAD therapy showed survival outcomes comparable to heart transplantation.
Support for the LVAD-first strategy as an initial treatment approach for selected patients.

Abstract

Contemporary data suggest that durable LVAD therapy may offer survival outcomes comparable to HT in adults <50 years of age. These findings support the consideration of an LVAD-first strategy as a viable initial approach to heart replacement therapy in appropriately selected patients. (Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 Investigational Device Exemption MOMENTUM 3 IDE; NCT02224755) (MOMENTUM 3 Continued Access Protocol MOMENTUM 3 CAP; NCT02892955).

Read Full Paperexternally

Ask AI

Helpful

Bookmark

View Full Paper